Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 15, 2015, Pages 6151-6178

  Bamborough, Paul ^a   Chung, Chun Wa ^a   Furze, Rebecca C ^a   Grandi, Paola ^b   Michon, Anne Marie ^b   Sheppard, Robert J ^a,c   Barnett, Heather ^a   Diallo, Hawa ^a   Dixon, David P ^a   Douault, Clement ^a   Jones, Emma J ^a   Karamshi, Bhumika ^a   Mitchell, Darren J ^a   Prinjha, Rab K ^a   Rau, Christina ^b   Watson, Robert J ^a   Werner, Thilo ^b   Demont, Emmanuel H ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (Germany)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODOMAIN INHIBITOR; NAPHTHYRIDONE DERIVATIVE; PROTEIN ATAD2; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; ATAD2 PROTEIN, HUMAN; DNA BINDING PROTEIN; NAPHTHYRIDINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIPOPHILICITY; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY;

ADENOSINE TRIPHOSPHATASES; DNA-BINDING PROTEINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAPHTHYRIDINES;

EID: 84939189418     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00773     Document Type: Article

References (30)

1. Caron, C.; Lestrat, C.; Marsal, S.; Escoffier, E.; Curtet, S.; Virolle, V.; Barbry, P.; Debernardi, A.; Brambilla, C.; Brambilla, E.; Rousseaux, S.; Khochbin, S. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers Oncogene 2010, 29, 5171-5181 10.1038/onc.2010.259
2. Boussouar, F.; Jamshidikia, M.; Morozumi, Y.; Rousseaux, S.; Khochbin, S. Malignant genome reprogramming by ATAD2 Biochim. Biophys. Acta, Gene Regul. Mech. 2013, 1829, 1010-1014 10.1016/j.bbagrm.2013.06.003
3. Zou, J. X.; Guo, L.; Revenko, A. S.; Tepper, C. G.; Gemo, A. T.; Kung, H. J.; Chen, H. W. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer Cancer Res. 2009, 69, 3339-3346 10.1158/0008-5472.CAN-08-3440
4. Dawson, M. A.; Kouzarides, T.; Huntly, B. J. Targeting epigenetic readers in cancer N. Engl. J. Med. 2012, 367, 647-657 10.1056/NEJMra1112635
5. Jennings, L. E.; Measures, A. R.; Wilson, B. G.; Conway, S. J. Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands Future Med. Chem. 2014, 6, 179-204 10.4155/fmc.13.197
6. Demont, E. H.; Chung, C.; Furze, R.; Grandi, P.; Michon, A. M.; Wellaway, C.; Barrett, N.; Bridges, A. M.; Craggs, P. D.; Diallo, H.; Dixon, D. P.; Douault, C.; Emmons, A.; Jones, E. J.; Karamshi, B.; Locke, K.; Mitchell, D. J.; Mouzon, B. H.; Prinjha, R. K.; Roberts, A. D.; Sheppard, R. J.; Watson, R. J.; Bamborough, P. Fragment-based discovery of low-micromolar ATAD2 bromodomain inhibitors J. Med. Chem. 2015, 58, 5649 10.1021/acs.jmedchem.5b00772
7. Muller, S.; Knapp, S. Discovery of BET bromodomain inhibitors and their role in target validation MedChemComm 2014, 5, 288-296 10.1039/c3md00291h
8. Chung, C.; Coste, H.; White, J. H.; Mirguet, O.; Wilde, J.; Gosmini, R. L.; Delves, C.; Magny, S. M.; Woodward, R.; Hughes, S. A.; Boursier, E. V.; Flynn, H.; Bouillot, A. M.; Bamborough, P.; Brusq, J. M.; Gellibert, F. J.; Jones, E. J.; Riou, A. M.; Homes, P.; Martin, S. L.; Uings, I. J.; Toum, J.; Clement, C. A.; Boullay, A. B.; Grimley, R. L.; Blandel, F. M.; Prinjha, R. K.; Lee, K.; Kirilovsky, J.; Nicodeme, E. Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains J. Med. Chem. 2011, 54, 3827-3838 10.1021/jm200108t
9. Gosmini, R.; Nguyen, V. L.; Toum, J.; Simon, C.; Brusq, J. M.; Krysa, G.; Mirguet, O.; Riou-Eymard, A. M.; Boursier, E. V.; Trottet, L.; Bamborough, P.; Clark, H.; Chung, C. W.; Cutler, L.; Demont, E. H.; Kaur, R.; Lewis, A. J.; Schilling, M. B.; Soden, P. E.; Taylor, S.; Walker, A. L.; Walker, M. D.; Prinjha, R. K.; Nicodeme, E. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor J. Med. Chem. 2014, 57, 8111-8131 10.1021/jm5010539
10. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C. W.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of inflammation by a synthetic histone mimic Nature 2010, 468, 1119-1123 10.1038/nature09589
11. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468, 1067-1073 10.1038/nature09504
12. Poncet-Montange, G.; Zhan, Y.; Bardenhagen, J. P.; Petrocchi, A.; Leo, E.; Shi, X.; Lee, G. R.; Leonard, P. G.; Geck Do, M. D.; Cardozo, M. K.; Andersen, M. G.; Palmer, J. N.; Jones, W. S.; Ladbury, P. J. E. Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2A Biochem. J. 2015, 466, 337-346 10.1042/BJ20140933
13. Li, X.; Russell, R. K.; Spink, J.; Ballentine, S.; Teleha, C.; Branum, S.; Wells, K.; Beauchamp, D.; Patch, R.; Huang, H.; Player, M.; Murray, W. Process Development for Scale-Up of a Novel 3, 5-Substituted Thiazolidine-2, 4-dione Compound as a Potent Inhibitor for Estrogen-Related Receptor 1 Org. Process Res. Dev. 2014, 18, 321-330 10.1021/op400325r
14. Fink, B. E.; Gavai, A. V.; Vite, G. D.; Chen, P.; Mastalerz, H.; Norris-Drouin, J.; Tokarski, J. S.; Zhao, Y.; Han, W. C. Pyrrolotriazine compounds as kinase inhibitors. PCT Int. Appl WO2005066176A1, 2005.
15. The BROMOscan panel, courtesy of DiscoveRx Corp. www.discoverx.com.
16. H17 cell differentiation Nat. Chem. Biol. 2012, 8, 576-582 10.1038/nchembio.957
17. Bantscheff, M.; Hopf, C.; Savitski, M. M.; Dittmann, A.; Grandi, P.; Michon, A. M.; Schlegl, J.; Abraham, Y.; Becher, I.; Bergamini, G.; Boesche, M.; Delling, M.; Dumpelfeld, B.; Eberhard, D.; Huthmacher, C.; Mathieson, T.; Poeckel, D.; Reader, V.; Strunk, K.; Sweetman, G.; Kruse, U.; Neubauer, G.; Ramsden, N. G.; Drewes, G. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes Nat. Biotechnol. 2011, 29, 255-265 10.1038/nbt.1759
18. Kruse, U.; Pallasch, C. P.; Bantscheff, M.; Eberhard, D.; Frenzel, L.; Ghidelli, S.; Maier, S. K.; Werner, T.; Wendtner, C. M.; Drewes, G. Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells Leukemia 2011, 25, 89-100 10.1038/leu.2010.233
19. Savitski, M. M.; Fischer, F.; Mathieson, T.; Sweetman, G.; Lang, M.; Bantscheff, M. Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays J. Am. Soc. Mass Spectrom. 2010, 21, 1668-1679 10.1016/j.jasms.2010.01.012
20. Bantscheff, M.; Eberhard, D.; Abraham, Y.; Bastuck, S.; Boesche, M.; Hobson, S.; Mathieson, T.; Perrin, J.; Raida, M.; Rau, C.; Reader, V.; Sweetman, G.; Bauer, A.; Bouwmeester, T.; Hopf, C.; Kruse, U.; Neubauer, G.; Ramsden, N.; Rick, J.; Kuster, B.; Drewes, G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 2007, 25, 1035-1044 10.1038/nbt1328
21. Sharma, K.; Weber, C.; Bairlein, M.; Greff, Z.; Keri, G.; Cox, J.; Olsen, J. V.; Daub, H. Proteomics strategy for quantitative protein interaction profiling in cell extracts Nat. Methods 2009, 6, 741-744 10.1038/nmeth.1373
22. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol.: Macromol. Crystallogr., Part A 1997, 276, 307-326 10.1016/S0076-6879(97)76066-X
23. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data Jt. CCP4 ESF-EACBM Newsl. 1992, 26, 29-35
24. Kabsch, W. XDS Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 125-132 10.1107/S0907444909047337
25. Evans, P. R. Data Reduction Proc. CCP4 Study Weekend, Data Collect. Process. 1993, 114-122
26. Evans, P. R.; Murshudov, G. N. How good are my data and what is the resolution? Acta Crystallogr., Sect. D: Biol. Crystallogr. 2013, 69, 1204-1214 10.1107/S0907444913000061
27. Collaborative Computational Project No.4 The CCP4 suite: programs for protein crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, D50, 760-763 10.1107/S0907444994003112
28. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255 10.1107/S0907444996012255
29. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132 10.1107/S0907444904019158
30. Dawson, M. A.; Prinjha, R. K.; Dittmann, A.; Giotopoulos, G.; Bantscheff, M.; Chan, W. I.; Robson, S. C.; Chung, C. W.; Hopf, C.; Savitski, M. M.; Huthmacher, C.; Gudgin, E.; Lugo, D.; Beinke, S.; Chapman, T. D.; Roberts, E. J.; Soden, P. E.; Auger, K. R.; Mirguet, O.; Doehner, K.; Delwel, R.; Burnett, A. K.; Jeffrey, P.; Drewes, G.; Lee, K.; Huntly, B. J.; Kouzarides, T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 2011, 478, 529-533 10.1038/nature10509